news
Taselisib boosts breast tumour shrinkage
According to results of the LORELEI clinical trial, adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer...
List view / Grid view
European Society for Medical Oncology (ESMO)
article
Biosimilars create opportunities for sustainable cancer care
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
news
Large study shows older breast cancer patients have worse outcomes
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18...
news
Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib...
news
Patient overall survival still strong three years after Novartis’ melanoma trial
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy...
news
Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase...
news
Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
6 July 2015 | By Victoria White
Results from a study on the efficacy of cetuximab plus FOLFOX chemo as second-line treatment for patients with mCRC were presented at the ESMO 2015 congress...
news
Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer
3 July 2015 | By Victoria White
The Phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)...
news
ESMO highlights the opportunities and challenges to come from the EU Clinical Trials Regulation
28 May 2015 | By Victoria White
ESMO, in collaboration with EORTC, have expressed their views on the EU Clinical Trials Regulation in an official position paper...
